 
        
						Elie Daccache 
	
					    												
Lebanon						                            
                            
						
 Research Article
												 Bioequivalence of Losartan/Amlodipine Fixed Dose Combination Tablets
(Losanet AM) Compared with Concomitant Administration of Single
Components of Losartan and Amlodipine Tablets in Healthy Human
Volunteers 
												
Author(s): Rana  Bustami, Sewar  Khasawneh, Wafaa’ Absi, Hamzeh  Feddah, Mohamad  Mroueh, Elie Daccache, Jean-Charles  Sarraf and Soula  KyriacosRana  Bustami, Sewar  Khasawneh, Wafaa’ Absi, Hamzeh  Feddah, Mohamad  Mroueh, Elie Daccache, Jean-Charles  Sarraf and Soula  Kyriacos             
						
												
				 A fixed dose combination of losartan, an angiotensin receptor blocker and amlodipine, a calcium channel blocker, can potentially provide complementary mechanism of action to improve blood pressure control and clinical outcomes. The current study was conducted to compare the pharmacokinetics of a new combination product of losartan potassium and amlodipine besylate with separate co-administration of losartan potassium and amlodipine besylate tablets in 40 healthy human volunteers after a single oral dose in a randomized three-period crossover study. The study protocol was prepared in accordance to the requirements set in the EMA guidance for conducting bioequivalence studies. Reference (Cozaar 100 mg, Merck Sharp & Dohme Ltd, UK and Norvasc 10 mg, Pfizer, Canada) and test (Losanet AM, Pharmaline, Lebanon) drugs were administered to fasted volunteers and blood samples were collected.. View More»
				  
												DOI:
												 10.4172/jbb.1000243